Steven D. Barrett


  • Co-Chair, Technology Transactions and Licensing Practice Group

Steve Barrett, co-chair of the Technology Transactions and Licensing Practice Group, advises a variety of life sciences and technology companies regarding the structuring, negotiation and drafting of agreements for a broad range of technology transactions, including technology acquisition, license, strategic alliance and joint venture transactions, and related research, development, supply, marketing, distribution and services agreements. Mr. Barrett regularly represents entrepreneurs, early-stage and established life sciences and technology companies and large commercial enterprises.

Learn more about Mr. Barrett's practice and how he can support your startup on

Community Involvement

Mr. Barrett serves on the board of directors of The Political Asylum/Immigration Representation (PAIR) Project. Mr. Barrett has also successfully represented, on a pro bono basis, a number of persons who have fled persecution in other countries and sought political asylum in the United States.

Mr. Barrett served on active duty as a US naval officer from 1989 to 1992. His assignments included division officer tours in USS Hoel (DDG-13) and USS Waddell (DDG-24), and he qualified as a surface warfare officer and was awarded the Navy Achievement Medal.


  • Mr. Barrett has represented:

    • Adimab in its antibody platform licensing agreements with GSK (2013), Biogen Idec (2013), Novo Nordisk (2013) and Merck (2015)
    • Agios Pharmaceuticals in its IDHIFA® royalty and milestone sale transaction with Royalty Pharma (2020)
    • Agios Pharmaceuticals in its Chinese territory collaboration and license agreement for Ivosidenib with CStone Pharmaceuticals (2018)
    • Agios Pharmaceuticals in its metabolic immuno-oncology collaborations with Celgene (2010 and 2016)
    • Apellis Pharmaceuticals in its complement-driven disease collaboration with Beam Therapeutics (2021)
    • Apellis Pharmaceuticals in its systemic pegcetacoplan collaboration with Sobi (2020)
    • Apellis Pharmaceuticals in its pegcetacoplan hematologic indication collaboration with SFJ Pharmaceuticals (2019)
    • Beam Therapeutics in its multi-target research collaboration for base editing programs for rare diseases with Pfizer (2022)
    • Carisma Therapeutics in its strategic collaboration agreement for in vivo engineered chimeric antigen receptor monocyte (CAR-M) cancer therapeutics with Moderna (2022)
    • Cybrexa Therapeutics in its collaboration and program acquisition option agreements for Cybrexa’s CBX-12 peptide-drug conjugate with Exelixis (2022)
    • D.E. Shaw Research in its exclusive license agreement for DES-7114 with Lilly (2022)
    • Editas Medicine in its amended collaboration for gene-edited autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases with Celgene (2019)
    • Editas Medicine in its gene editing and cell therapy platform collaboration with BlueRock Therapeutics (2019)
    • Editas Medicine in its licensing agreement for base editing technology with Beam Therapeutics (2018)
    • Editas Medicine in its strategic alliance and option agreement with Allergan (2017)
    • Editas Medicine in its licensing of CRISPR technologies from the Broad Institute, MIT, Harvard and other academic institutions (2016)
    • Epizyme in its Tazverik royalty sale transaction with Royalty Pharma (2019)
    • Epizyme in its combination clinical trial collaboration with Genentech (2016)
    • Incyte in its worldwide collaboration and licensing agreement for axatilimab with Syndax Pharmaceuticals (2021)
    • Iveric Bio in its >$1 billion ex-US licensing and commercialization agreement for FOVISTA with Novartis (2014)
    • Lexicon in its worldwide collaboration and licensing agreement for sotagliflozin with Sanofi (2015)
    • Lexicon in its ex-US and Japan licensing agreement for telotristat etiprate with Ipsen (2014)
    • MacroGenics in its anti-PD-1 monoclonal antibody collaboration with Incyte (2017)
    • Mersana Therapeutics in its worldwide collaboration, option and license agreement for XMT-2056 with GlaxoSmithKline (2022)
    • Novo Nordisk in its cardiometabolic and rare disease collaboration with Flagship Pioneering (2022)
    • Novo Nordisk in its RNAi therapy collaboration for liver-related cardio-metabolic diseases with Dicerna Pharmaceuticals (2019)
    • Ocular Therapeutix in its Asian territory collaboration and license agreement for DEXTENZA and OTX-TIC with AffaMed (2020)
    • PTC Therapeutics in its Risdiplam royalty monetization agreement with Royalty Pharma (2020)
    • Repare Therapeutics in its worldwide license and collaboration agreement for Camonsertib (RP-3500) with Roche (2022)
    • Repare Therapeutics in its synthetic lethal oncology target discovery collaboration with Bristol-Myers Squibb (2020)
    • Ribometrix in its RNA-targeted small molecule therapeutic discovery and development collaboration with Genentech (2020)
    • Ribometrix in its RNA-targeted small molecule therapeutic discovery and development collaboration with Vertex Pharmaceuticals (2019)
    • Ribon Therapeutics in its Asian territory collaboration and license agreement for RBN-2397 with Ono Pharmaceutical Co., Ltd. (2021)
    • Spark Therapeutics in its ex-US licensing and commercialization agreement for LUXTURNA with Novartis (2018)
    • Vividion Therapeutics in its small molecule ubiquitin proteome collaboration with Celgene (2018)
    • vTv Therapeutics in its licensing agreements with Reneo Pharmaceuticals (2017), Newsoara Biopharma Co. (2018) and Anteris (2020)


  • Recognized in the 2024 Chambers Global Guide for his life sciences practice.
  • Recognized in the 2023–2024 editions of Chambers USA Guide for his life sciences practice (Nationwide and Massachusetts).
  • Selected by his peers for inclusion in the 2021–2024 editions of the Best Lawyers in America in the biotechnology and life sciences practice category.
  • Recognized for his practice and named a "Life Sciences Star" in the 2012–2023 editions of LMG Life Sciences and named to its 2017 awards shortlist for Finance & Transactional Attorney of the Year: Licensing & Collaboration. He was also awarded one of five Finance and Transactional Impact Cases of the Year by LMG for counseling Editas Medicine in its licensing and collaboration with Allergan.
  • Recommended in the 2019 edition of The Legal 500 United States for his work in Healthcare: Life Sciences, Commercial Deals and Contracts and Technology Transactions. In the 2016, 2017 and 2018 editions, he was recommended in the areas of M&A/Corporate and Commercial and Media, Technology and Telecoms: Outsourcing and Transactions.
  • Recognized as a leader in life sciences in the 2015 and 2016 editions of Who's Who Legal.
  • Recognized in each edition of the PLC Cross-border Life Sciences Handbook in the USA Commercial and Partnering category since the 2006/07 edition; listed as Leading in this category in the 2009/10 and 2011/12 editions.
  • Named "Massachusetts Super Lawyer" in the areas of intellectual property and business/corporate law in 2014–2016 and 2023.
  • Named a "Massachusetts Super Lawyers Rising Star" in intellectual property law in the 2005 and 2006 issues of Boston Magazine.

Insights & News


  • Education

    • JD, University of Michigan Law School, 1996

      cum laude
    • MBA, University of Michigan, 1996

      with High Distinction
    • SB, Mechanical Engineering, Massachusetts Institute of Technology, 1989

  • Admissions

    • Massachusetts

    • Michigan

    • US Patent and Trademark Office



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.